| 证券代码：603716 | 证券简称：塞力医疗 公告编号：2023-057 | | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | 塞力斯医疗科技集团股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： http://roadshow.sseinfo.com/），中国证券报·中证网 （https://www.cs.com.cn/roadshow/yjsmh/） 会议召开方式：上证路演中心视频直播和网络互动、中证网路演中心网络 互动 投资者可于 2023 年 5 月 15 日（星期一）至 5 月 19 日（星期五）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@thaly.net.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 塞力斯医疗科技集团股份有限公司（以下简称"公司"）已于 2023 年 4 月 27 日发布公司 2022 年度报告，为便于广大投资者更全面深入 ...

Financial Performance - In Q1 2023, the company reported revenue of CNY 444.07 million, a decrease of 23.29% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of CNY 14.91 million, representing a decline of 170% year-on-year[5]. - The basic earnings per share were CNY -0.07, a decrease of 173.25% compared to the same period last year[5]. - In Q1 2023, the company reported a net loss of CNY 6,651,427.65, compared to a net profit of CNY 25,738,000.43 in Q1 2022, indicating a significant decline in profitability[28]. - The company’s total comprehensive loss for the period was CNY 7,511,690.31, compared to a comprehensive income of CNY 21,546,216.99 in the same quarter last year[28]. Revenue Breakdown - The IVD business revenue was CNY 296.80 million, accounting for 66.79% of total revenue, down 5.91 percentage points from the previous year[7]. - Total operating revenue for Q1 2023 was ¥444,069,353.53, a decrease of 23.3% compared to ¥578,884,225.92 in Q1 2022[26]. - The total revenue from operating activities was CNY 587,950,514.74, an increase from CNY 459,800,471.28 in the same period last year, reflecting a growth of approximately 27.8%[29]. Expenses and Costs - Total expenses increased by 3.81% year-on-year to CNY 108 million, primarily due to increased sales and management expenses[10]. - Total operating costs for Q1 2023 were ¥455,311,016.55, down 15.7% from ¥540,110,563.59 in Q1 2022[26]. - Research and development expenses for Q1 2023 amounted to ¥7,450,644.90, a decrease of 13.6% from ¥8,630,117.36 in Q1 2022[26]. Cash Flow and Liquidity - The company’s cash flow from operating activities was CNY 38.64 million, which is not comparable to the previous period[5]. - The company reported a net cash flow from operating activities increase due to higher sales receipts[19]. - The company experienced a net cash flow from operating activities of CNY 38,642,551.81, a recovery from a negative cash flow of CNY 117,248,727.93 in Q1 2022[30]. - The company’s cash and cash equivalents decreased to 270.29 million from 394.54 million year-over-year[22]. - The company’s cash and cash equivalents at the end of Q1 2023 were CNY 261,908,897.81, down from CNY 406,322,679.30 at the end of Q1 2022, representing a decrease of approximately 35.5%[30]. Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 3.74 billion, down 5.30% from the end of the previous year[6]. - Total assets decreased to ¥3,738,068,484.78 in Q1 2023 from ¥3,947,450,797.29 in Q1 2022, reflecting a decline of 5.3%[25]. - Total liabilities decreased by 34.67 million due to repayment of long-term borrowings[19]. - Total liabilities decreased to ¥2,246,130,033.44 in Q1 2023 from ¥2,450,479,523.67 in Q1 2022, a reduction of 8.3%[24]. - Current assets totaled ¥2,755,718,512.10 in Q1 2023, down from ¥2,950,562,653.79 in Q1 2022, a decrease of 6.6%[24]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 25,534[18]. - The largest shareholder, Shanghai Saihai Health Technology Co., Ltd., holds 25,042,470 shares, representing 12.30% of total shares[19]. Strategic Initiatives - The company is undergoing a strategic transformation towards medical intelligence, which has impacted revenue from traditional IVD business[6]. - The company received government grants totaling 364.60 million, contributing positively to other income[19].

Financial Performance - The net profit attributable to shareholders for 2022 was -154,417,230.00 CNY, with cumulative distributable profits amounting to 411,784,160.60 CNY[5] - The parent company reported a net profit of -58,385,751.04 CNY for 2022, with cumulative distributable profits of 314,868,620.89 CNY[5] - The company plans not to distribute cash dividends for the 2022 fiscal year and will not increase capital reserves[5] - The company's revenue for 2022 was approximately CNY 2.31 billion, a decrease of 11.19% compared to CNY 2.60 billion in 2021[23] - The net loss attributable to shareholders for 2022 was CNY 154.42 million, compared to a loss of CNY 49.51 million in 2021[23] - The net cash flow from operating activities was CNY 28.12 million, a significant improvement from a negative cash flow of CNY 133.52 million in 2021[23] - Total assets decreased by 8.06% to CNY 3.95 billion in 2022 from CNY 4.29 billion in 2021[25] - The company reported a significant increase in credit impairment losses due to delayed receivables, amounting to CNY 34.24 million for specific clients undergoing bankruptcy restructuring[26] - The gross profit margin for the IVD segment decreased by 1.49 percentage points to 45.10% in 2022[27] - The basic earnings per share for 2022 was -CNY 0.79, compared to -CNY 0.25 in 2021[30] - The weighted average return on equity was -10.98% in 2022, down from -3.09% in 2021[30] Operational Developments - The company reported a comprehensive range of medical technology services, including centralized procurement and logistics support for medical institutions[12] - The annual report highlighted a focus on molecular diagnostics and point-of-care testing (POCT) technologies, which are critical for enhancing diagnostic accuracy[13] - The company is actively pursuing the establishment of regional inspection centers to support tiered diagnosis and treatment policies, aiming to improve healthcare delivery in local communities[13] - The implementation of a smart supply chain management platform is expected to enhance operational efficiency and reduce costs for medical institutions[14] - The company is committed to achieving CE certification for its products, ensuring compliance with European market standards[13] - The report indicated a strategic emphasis on expanding the company's presence in the medical supply chain sector, particularly in the context of integrated management solutions[14] - The company aims to leverage big data for disease diagnosis and treatment, enhancing its capabilities in healthcare management and reimbursement systems[13] - The annual report noted a focus on research and development of diagnostic reagents and self-built testing methods in laboratories[14] - The company is exploring opportunities for mergers and acquisitions to strengthen its market position and expand its service offerings[12] Strategic Initiatives - The future outlook includes a commitment to enhancing the quality of medical services through innovative technologies and comprehensive management solutions[12] - The company is focusing on a dual business model of "SPD+IVD" to enhance its position as a comprehensive service provider in the smart hospital ecosystem[38] - The strategic plan includes expanding into upstream advanced in vitro diagnostic technologies and outpatient services, aiming to increase market share in the IVD sector[41] - The company aims to enhance customer retention by integrating its own products into existing client systems, thereby increasing revenue and profit continuity[41] - New projects in molecular diagnostics are being introduced to leverage existing resources and improve market share in this area[41] - The company is committed to optimizing its organizational structure and extending its industrial ecosystem to support business development[39] - The company has signed smart medical industry park projects in Chongqing and Liangshan, creating regional SPD project models to capture more market share through localized cooperation[43] - The company aims to build a broad market smart medical ecosystem by leveraging innovative technology, localized services, and channel advantages, responding to the expanding county-level medical market[45] - The company is actively promoting the construction of smart medical digital industry parks to assist in the digital transformation of grassroots medical health services[51] Market Trends and Challenges - The IVD industry in China is experiencing rapid growth due to increasing healthcare spending and an aging population, leading to a sustained demand for medical products and services[54] - The average cost proportion of medical consumables in hospitals with a revenue scale of 1 billion is between 23% and 25%, while hospitals with over 2 billion can reach 33% to 34%[58] - The SPD business is expected to see a continuous increase in demand over the next five years, driven by policy support and the need for refined management in hospitals[62] - The company is positioned as a leading player in the medical consumables market, benefiting from high barriers to entry and a competitive landscape dominated by large enterprises[62] - The company has established regional inspection centers to enhance the quality of medical services, integrating resources to reduce costs and improve testing quality for grassroots medical institutions[64] Governance and Compliance - The company has received a qualified audit opinion from Zhongzheng Zhonghuan Accounting Firm[4] - The board of directors and management have confirmed the accuracy and completeness of the annual report[6] - The company has not provided guarantees in violation of decision-making procedures[7] - The report includes a detailed description of potential risks that the company may face in the future[7] - The company has established a long-term mechanism to prevent fund occupation by controlling shareholders and related parties[140] - The board of directors held 14 meetings during the reporting period, ensuring compliance with governance standards[137] - The company received regulatory warnings from the Shanghai Stock Exchange on July 15, 2022, and was criticized for its management practices, including the actions of its former chairman and general manager[160] - On September 30, 2022, the company was issued a warning letter by the Hubei Securities Regulatory Bureau, which was recorded in the securities market integrity archive[161] - The company was subject to multiple disciplinary actions throughout 2022, including a public reprimand on November 3, 2022, for governance issues involving key executives[162] - In January 2023, the company received an order for rectification from the Hubei Regulatory Bureau, emphasizing the need to improve corporate governance and compliance with regulations[162] Human Resources and Talent Management - The total number of employees in the parent company is 295, while the main subsidiaries employ 1,179, resulting in a total of 1,474 employees[175] - The company has a diverse educational background among employees, with 46 holding postgraduate degrees and 494 having bachelor's degrees[175] - The company emphasizes a competitive and effective compensation policy to motivate employees, linking pay to performance and company results[177] - Training programs are organized to enhance employee skills and core competitiveness, including various training methods such as internal and external training[178] - The company is enhancing its talent acquisition strategy to ensure a supply of skilled professionals to meet the increasing demand in the smart healthcare market[130] Research and Development - The company is prioritizing research and development in innovative healthcare solutions to meet market demands[156] - The company has registered 17 new product certificates during the reporting period, increasing the total to 195[100] - The company is actively pursuing new technology development to improve its diagnostic capabilities[147] - The company is investing $50 million in new product development, focusing on innovative medical technologies[148] Future Outlook - The company plans to expand its market presence by entering three new regions in 2023, aiming for a 15% increase in market share[148] - The company has set a performance guidance for the next fiscal year, projecting a revenue increase of 20%[148] - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[148] - The company plans to recover 1 billion in accounts receivable in 2023, which will significantly alleviate financial pressure and enhance net profit margins[129]

Financial Performance - The company's operating revenue for Q3 2022 was approximately CNY 612.60 million, representing a year-on-year decrease of 2.48%[5]. - The net profit attributable to shareholders for Q3 2022 was a loss of CNY 6.69 million, compared to a profit of CNY 8.58 million in the same period last year, marking a decline of 684.65%[5][7]. - For the first nine months of 2022, the total revenue was CNY 1.76 billion, down 3.48% year-on-year due to the ongoing impact of the pandemic and contract terminations[7]. - Total operating revenue for the first three quarters of 2022 was CNY 1,762,497,864.80, a decrease of 3.46% compared to CNY 1,825,974,014.36 in the same period of 2021[24]. - The company's net profit for the first three quarters of 2022 was impacted by a credit impairment loss of CNY -27,621,805.10, compared to CNY -13,890,700.18 in the previous year[24]. - The net profit for Q3 2022 was CNY 16,478,299.16, a decrease of 19.5% compared to CNY 20,355,739.76 in Q3 2021[25]. - The total profit for Q3 2022 was CNY 27,693,271.83, down from CNY 31,093,128.40 in the same period last year, reflecting a decline of 11.5%[25]. - The operating profit for Q3 2022 was CNY 28,741,567.50, compared to CNY 31,746,879.44 in Q3 2021, indicating a decrease of 9.5%[25]. Assets and Liabilities - The total assets at the end of Q3 2022 were CNY 4.18 billion, a decrease of 2.64% compared to the end of the previous year[6]. - Cash and cash equivalents as of September 30, 2022, were CNY 261,866,405.66, a decrease from CNY 473,549,725.12 at the end of 2021[20]. - Total assets as of September 30, 2022, were CNY 4,180,328,732.37, a decrease from CNY 4,293,573,705.49 at the end of 2021[22]. - Total liabilities decreased to CNY 2,455,822,235.01 from CNY 2,550,662,118.81 at the end of 2021, reflecting a reduction of 3.72%[22]. - The company's equity attributable to shareholders was CNY 1,538,508,098.96 as of September 30, 2022, down from CNY 1,562,078,741.56 at the end of 2021[22]. Cash Flow - The company reported a cash flow from operating activities of CNY 93.99 million for the first nine months of 2022[6]. - The cash flow from operating activities for the first nine months of 2022 was CNY 93,998,800.15, a significant improvement from a negative cash flow of CNY -198,098,122.87 in the same period of 2021[30]. - The total cash inflow from operating activities for the first nine months of 2022 was CNY 1,925,750,719.47, compared to CNY 1,830,535,426.66 in 2021, representing an increase of 5.2%[29]. - The cash flow from investing activities for the first nine months of 2022 was negative at CNY -26,471,555.97, an improvement from CNY -138,015,120.50 in the same period of 2021[30]. - The cash flow from financing activities for Q3 2022 was negative at CNY -285,859,867.03, compared to a positive cash flow of CNY 164,792,623.38 in Q3 2021[30]. Expenses and Provisions - Sales expenses increased by CNY 10.59 million, primarily due to the rise in salaries and benefits for sales personnel related to the new business with Johnson & Johnson[8]. - Financial expenses rose by CNY 10.29 million, attributed to increased financing costs[8]. - The company experienced a significant increase in credit impairment provisions, which rose by 98.85% year-on-year, amounting to an additional CNY 13.73 million[8]. - Research and development expenses decreased by 34.95% due to reduced material input and testing costs[14]. - Research and development expenses for the first three quarters of 2022 were CNY 16,811,524.37, a decrease from CNY 25,843,322.03 in the same period of 2021, indicating a reduction of 34.93%[24]. Revenue Sources - The revenue from the Hubei Provincial Tumor Hospital's contracts decreased by approximately 10.22%, resulting in a loss of CNY 49.32 million[12]. - The revenue from the subsidiary Shandong Selis Medical Technology Co., Ltd. decreased by approximately 76.02%, resulting in a loss of CNY 57.22 million due to contract terminations[12]. - Total revenue for Q3 2022 was 2,578,446.09, a decrease from 3,578,063.73 in the same period last year[13]. Other Financial Metrics - Cash and cash equivalents decreased by 44.70% due to a reduction in bank deposits[13]. - Trade financial assets decreased by 95.33% primarily due to the redemption of wealth management products[13]. - Accounts receivable decreased by 72.53% as a result of reduced receivables[13]. - Prepayments increased by 80.42% due to an increase in advance payments for goods[13]. - Long-term equity investments decreased by 45.82% due to the transfer of some long-term investments to other equity instruments[13]. - The company reported a 263.63% increase in accounts payable due to increased settlements using notes payable[13]. - Investment income decreased by 76.35% primarily due to reduced investment losses[14]. - The company had a total of 19,331 common shareholders at the end of the reporting period[16].

Financial Performance - The company reported a half-year revenue of 1.2 billion RMB, representing a 15% increase compared to the same period last year[1]. - The company's operating revenue for the first half of 2022 was approximately ¥1.15 billion, a decrease of 4.00% compared to ¥1.20 billion in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2022 was approximately ¥1.68 million, down 48.51% from ¥3.26 million in the previous year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥680,476, a decrease of 46.02% compared to ¥1.26 million in the same period last year[21]. - The company reported a total revenue of 25,015.62 million RMB from the acquisition of Jingyang Teng, with a net profit of 1,029.09 million RMB, reflecting a significant contribution to overall performance[75]. - The company reported a total of 381.67 million in loan disputes, with no judgments made yet[107]. - The company reported a significant increase in revenue, achieving a total of 212.83 million RMB from loan disputes during the reporting period[105]. - The company reported a net profit of -10,184,964, indicating a significant decrease in profitability compared to the previous period[163]. User Growth and Market Expansion - User data indicates a growth in active users by 20%, reaching 500,000 users by the end of the reporting period[1]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share within the next two years[1]. - The company aims to expand its market presence through the dual business model of IVD and SPD, focusing on both internal and external growth drivers[51]. - The company is focusing on channel mergers, market expansion, and strategic cooperation to strengthen nationwide terminal channel coverage[82]. - The user base grew by 85% compared to the previous period, showcasing strong market demand[163]. Research and Development - Research and development expenses increased by 30%, totaling 150 million RMB, focusing on innovative medical technologies[1]. - The company is committed to developing new technologies and products in the field of in vitro diagnostics and molecular diagnostics[21]. - The company is investing in new technology development, with a budget allocation of 1,327,853.0 million for R&D initiatives[164]. - The company has built a strong development team focused on integrating IoT, blockchain, and AI technologies to support the transition to intelligent medical supply chain services[49]. - Research and development expenses decreased to CNY 13,914,378.73, down from CNY 18,111,647.95 in the same period last year[148]. Financial Position and Assets - The total assets at the end of the reporting period were approximately ¥4.27 billion, a decrease of 0.55% from ¥4.29 billion at the end of the previous year[21]. - The company's total assets at the end of the reporting period were approximately 1,602,136,5 RMB, showing a substantial asset base[179]. - The company's total liabilities decreased by 48.07% to ¥102,193,755.15, down from ¥196,808,883.01 in the previous year[66]. - The total equity attributable to shareholders decreased to CNY 1,551,893,776.71 from CNY 1,562,078,741.56[142]. - The company's cash and cash equivalents decreased by 47.32% to ¥249,456,876.79, down from ¥473,549,725.12 in the previous year[65]. Operational Efficiency and Cost Management - The company is focusing on enhancing its integrated operation services for medical testing and consumables through smart supply chain management[21]. - The company is implementing strategies to accelerate accounts receivable collection to improve cash flow, as the collection period has lengthened due to tightened medical insurance payments[60]. - The company is actively promoting the LeviCell™ system for liquid magnetic levitation cell sorting in the Chinese market, targeting leading research institutions and biotech companies[58]. - New strategies are being implemented to improve operational efficiency and reduce costs by approximately 10% over the next year[170]. - The company's operating costs decreased by 5.87%, from ¥941,919,577.53 to ¥886,647,573.20[62]. Risks and Challenges - The company has outlined various operational risks and corresponding mitigation strategies in the report[1]. - The company is facing risks from industry policy changes, particularly in medical insurance cost control and payment reform, which may lead to price reductions for certain reagent products[82]. - Increased market competition is anticipated as the industry matures, with more potential entrants and existing competitors improving their technology and service capabilities[82]. - The company is experiencing growing accounts receivable and funding pressure due to long payment cycles from major clients, which could lead to increased capital costs and reduced capital efficiency[83]. - Internal control and operational management risks are heightened due to rapid company growth and the complexity of post-merger integration[82]. Corporate Governance and Compliance - The board of directors has confirmed the authenticity and completeness of the financial report[1]. - There are no violations of decision-making procedures regarding external guarantees[1]. - The company has not proposed any profit distribution or capital reserve increase for the half-year period[87]. - The company has committed to ensuring that its compensation system for directors and senior management is linked to the execution of its performance compensation measures[101]. - The company received a criticism notice from the Shanghai Stock Exchange on July 25, 2022, due to non-compliance in the use and management of raised funds, leading to inaccurate performance forecasts for 2021[108]. Incentive Plans and Employee Engagement - The company plans to grant up to 5,053,530 restricted stocks as part of its incentive plan[89]. - The incentive plan aims to align the interests of employees with those of shareholders[89]. - The company has unlocked a total of 1,231,882 restricted shares, accounting for 0.60% of the total share capital[90]. - The first unlocking period for the restricted stock incentive plan has been achieved, with all conditions met for full unlocking[89]. - The company has not received any objections regarding the incentive plan from the public during the disclosure period[89].

债券代码：113601 债券简称：塞力转债 证券代码：603716 证券简称：塞力医疗 公告编号：2022-041 塞力斯医疗科技集团股份有限公司 关于参加 2022 年湖北辖区上市公司投资者集体接待日活动 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为便于广大投资者全面了解塞力斯医疗科技集团股份有限公司（以下简称 "公司"） 业绩、公司治理、经营状况、可持续发展等投资者所关心的问题， 加强公司与投资者之间的沟通交流，公司将参加由湖北省证监局、湖北省上市公 司协会与深圳市全景网络有限公司联合举办的"2022 年湖北辖区上市公司投资 者集体接待日暨 2021 年度业绩说明会"主题活动。现将有关事项公告如下： 本次集体接待日活动将通过深圳全景网络有限公司提供的网上平台，采取网 络远程的方式举行。投资者可以登录"全景路演"网站（http://rs.p5w.net/） 或关注微信公众号"全景财经"，或下载全景路演 APP，参与公司本次投资者网 上集体接待日活动。活动时间为 2022 年 6 月 16 日（星期四）13 ...

Financial Performance - The company's operating revenue for Q1 2022 was ¥578,884,225.92, representing a year-on-year increase of 12.01%[5] - The net profit attributable to shareholders for the same period was ¥21,185,477.22, showing a significant increase of 312.06% compared to the previous year[5] - The basic earnings per share for Q1 2022 was ¥0.10, which is an increase of 233.33% year-on-year[6] - Net profit for Q1 2022 reached CNY 25,738,000.43, representing a 84.9% increase from CNY 13,929,273.44 in Q1 2021[21] - Total operating revenue for Q1 2022 was CNY 578,884,225.92, an increase of 12.0% compared to CNY 516,817,163.09 in Q1 2021[20] - Total operating costs for Q1 2022 were CNY 540,110,563.59, up 7.8% from CNY 500,686,972.10 in Q1 2021[20] - The total comprehensive income for Q1 2022 was CNY 21,546,216.99, compared to CNY 13,200,661.86 in Q1 2021[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,489,441,503.44, reflecting a growth of 4.56% from the end of the previous year[6] - Total liabilities as of Q1 2022 amounted to CNY 2,724,732,419.09, an increase from CNY 2,550,662,118.81 in the previous year[19] - The company reported a total non-current asset value of RMB 1,038,715,874.68, slightly down from RMB 1,051,540,970.72[17] - The total current liabilities decreased to RMB 1,200,000,000 from RMB 1,300,000,000, indicating a reduction of approximately 7.7%[16] Cash Flow - The net cash flow from operating activities was negative at -¥117,248,727.93, indicating a decrease in cash inflow from operations[5] - Cash inflow from operating activities in Q1 2022 was $459,800,471.28, a decrease of 19.3% compared to $569,643,485.49 in Q1 2021[24] - Net cash outflow from operating activities in Q1 2022 was -$117,248,727.93, compared to -$11,996,421.08 in Q1 2021, indicating a significant decline[25] - Cash inflow from investment activities in Q1 2022 totaled $12,964,949.90, down from $60,000.00 in Q1 2021[25] - Net cash outflow from investment activities in Q1 2022 was -$52,516,502.00, compared to -$40,285,175.42 in Q1 2021, reflecting increased investment expenditures[25] - Cash inflow from financing activities in Q1 2022 was $415,094,729.82, an increase from $382,481,827.88 in Q1 2021[25] - Net cash inflow from financing activities in Q1 2022 was $106,935,733.09, compared to $36,667,810.27 in Q1 2021, indicating improved financing conditions[25] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 25,492[12] - The largest shareholder, Saihai (Shanghai) Health Technology Co., Ltd., held 29.68% of the shares, amounting to 60,843,770 shares[12] Other Financial Metrics - The weighted average return on equity increased by 1.09 percentage points to 1.43%[6] - The company experienced a 93.12% decrease in trading financial assets, primarily due to the sale of wealth management products[10] - The company's cash and cash equivalents decreased to RMB 413,977,088.37 from RMB 473,549,725.12, reflecting a decline of approximately 12.6%[16] - Accounts receivable increased to RMB 1,869,356,975.69, up from RMB 1,751,902,181.52, indicating a growth of about 6.7%[16] - Other receivables rose significantly to RMB 472,971,816.65 from RMB 346,411,293.27, representing an increase of approximately 36.5%[17] - Inventory levels increased to RMB 488,002,808.59 from RMB 463,613,082.08, showing a growth of about 5.2%[17] - The company has not provided specific guidance for future performance or new product developments in the current report[15] - Research and development expenses for Q1 2022 were CNY 8,630,117.36, a decrease of 10.1% from CNY 9,603,868.15 in Q1 2021[20] - Other income for Q1 2022 was CNY 153,017.18, down significantly from CNY 2,480,390.50 in Q1 2021[20] - The company reported a credit impairment loss of CNY -3,566,099.79 in Q1 2022, compared to CNY -755,312.73 in Q1 2021[21] - Cash paid to employees in Q1 2022 was $56,812,902.26, an increase of 11.9% from $50,763,857.20 in Q1 2021[25] - Cash paid for taxes in Q1 2022 was $42,369,049.26, up from $28,588,936.47 in Q1 2021, reflecting higher tax obligations[25] - Cash paid for other operating activities in Q1 2022 was $82,395,945.86, significantly higher than $39,750,824.11 in Q1 2021, indicating increased operational costs[25]

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year 2021, representing a growth of 15% compared to the previous year[22]. - The company achieved operating revenue of CNY 2,599,547,348.18 in 2021, representing a 22.30% increase compared to CNY 2,125,471,603.95 in 2020[23]. - The total revenue from SPD business grew to CNY 6.93 billion in 2021, a 95.63% increase from CNY 3.54 billion in 2020[24]. - The company achieved approximately CNY 2.6 billion in revenue for 2021, representing a year-over-year growth of about 22.30%[38]. - The revenue from the "Medical Consumables Centralization (SPD)" segment reached CNY 692.69 million, a significant increase of 95.63% compared to the previous year[41]. - The company reported a net profit attributable to shareholders was CNY -49,505,703.43, a decrease of 186.00% from CNY 57,561,565.34 in the previous year[24]. - The net cash flow from operating activities was CNY -133,523,631.54, a significant decline from CNY 9,944,111.48 in 2020, marking a decrease of 1,442.74%[24]. - The basic earnings per share were CNY -0.25, down 186.21% from CNY 0.29 in 2020[28]. - The company's net profit attributable to shareholders, excluding non-recurring gains and losses, was a loss of RMB 5,063,120, which is a decline of 183.61% compared to the previous year[79]. Strategic Development - The company is in a transition phase from a medical consumables operator to a smart medical service provider, requiring significant funding for overall strategic development[6]. - The company is focusing on long-term shareholder interests during its strategic transition[6]. - The company has set a future outlook with a revenue target of 1.5 billion RMB for 2022, indicating a projected growth rate of 25%[22]. - The company is committed to becoming a lifecycle management service provider for medical consumables, focusing on waste management to reduce carbon emissions[181]. - The company is exploring opportunities in medical waste management to enhance its competitiveness in line with national carbon neutrality goals[121]. - The company is committed to achieving carbon neutrality by exploring energy-saving and carbon-reduction strategies in medical waste management[47]. Research and Development - The company is investing in R&D, allocating 100 million RMB for the development of innovative medical technologies over the next two years[22]. - R&D expenses increased by CNY 15,940,900 compared to 2020, reflecting a strategic focus on medical information technology[27]. - The company’s R&D expenses totaled approximately ¥35.47 million, representing 1.36% of total revenue, with an increase of 81.62% compared to the previous year[94]. - The company has built a research and production platform for in vitro diagnostic reagents in Hubei and Hunan, focusing on various testing categories[74]. - The company has integrated advanced technologies, including liquid magnetic levitation and microfluidic cell sorting, to enhance its product competitiveness[76]. - The company is developing therapeutic vaccines for chronic diseases, including hypertension, and has established strategic cooperation for the development of a therapeutic antihypertensive vaccine[117]. Market Expansion - User data showed an increase in the number of medical institutions served, reaching 500, which is a 20% increase year-over-year[22]. - The company is expanding its market presence by entering three new provinces, aiming to increase its market share by 10% in the next fiscal year[22]. - The company has signed procurement service projects with several hospitals, including Fujian Fuding General Hospital and Jiangyin People's Hospital, to enhance its market presence[41]. - The company aims to enhance its market share in IVD, SPD, and RMCL businesses while improving the medical supply chain service system through modern information technology and intelligent equipment[105]. Governance and Compliance - The company has received a standard unqualified audit report from Zhongshun Zhonghuan Accounting Firm[5]. - The board of directors has confirmed that all members attended the board meeting, ensuring accountability for the report's accuracy[4]. - The company has implemented a registration system for insider information to enhance transparency and prevent insider trading[135]. - The company maintained independence from its controlling shareholder in personnel, assets, finance, and operations, ensuring independent accounting and risk management[135]. - The company has a structured process for determining the remuneration of senior management, which is subject to board approval[149]. - The company has not faced any penalties from securities regulatory agencies in the past three years[151]. Risk Management - The company has detailed potential risks in the management discussion and analysis section of the report[8]. - The company emphasizes the importance of investor awareness regarding the risks associated with forward-looking statements[7]. - The company faces risks related to industry policy changes, intensified market competition, and increasing accounts receivable pressures[127][128][129]. - The company is focusing on accelerating accounts receivable collection to improve cash flow, particularly due to extended payment cycles from hospitals since the pandemic[53]. Employee and Management Structure - The company expanded its workforce from over 1,300 employees in 2020 to over 1,600 employees by the end of 2021 to support business growth[38]. - The company has a diverse management team with extensive experience in various sectors, including medical diagnostics and financial management[140]. - The company has established a performance evaluation system for senior management, linking their performance assessment to annual operational targets set by the board of directors[176]. - The company has implemented a competitive compensation system based on performance and position, with a focus on long-term incentives aligned with strategic goals[168]. Legal and Regulatory Matters - The company is currently involved in several significant litigation and arbitration matters, as disclosed in announcements dated November 17, 2021, and subsequent updates[196]. - The company has ongoing contract disputes with Shandong Runchen Medical Technology Co., Ltd. and Huazhong Shandong Pharmaceutical Co., Ltd.[196]. - The company has not reported any measures to address potential delisting risks[196]. - The company has not disclosed any financial advisor or sponsor for the fiscal year[194].

Financial Performance - The company achieved operating revenue of RMB 628.19 million in Q3 2021, representing a year-on-year increase of 7.36%[5] - The net profit attributable to shareholders was a loss of RMB 2.41 million, a decline of 111.50% compared to the same period last year[5] - The company reported a total operating revenue of RMB 1.83 billion for the first three quarters of 2021, up 34.59% year-on-year[7] - The SPD business generated RMB 482 million in revenue, a significant increase of 120.22% year-on-year, accounting for 26% of total revenue[12] - The IVD business revenue was RMB 1.34 billion, reflecting an 18.12% year-on-year growth, but the gross margin decreased by 3.15% due to policy impacts[9] - Revenue for the year-to-date period increased by 34.59%, primarily driven by the gradual rollout of the SPD project, which generated revenue of 482 million CNY, a significant year-on-year growth of 120.22%[21] - IVD business achieved revenue of 1.344 billion CNY, representing a year-on-year increase of 18.12%[21] - Net profit attributable to shareholders decreased by 97.00% year-to-date, mainly due to a decline in gross margin, increased R&D investment, and rising financing costs[21] - The net profit attributable to shareholders, excluding non-recurring gains and losses, decreased by 104.19% year-to-date[21] - Basic and diluted earnings per share for the year-to-date period both decreased by 100.00%, attributed to the reduction in net profit[21] Research and Development - R&D expenses increased to RMB 25.84 million, a substantial rise of 270.58% year-on-year, reflecting the company's commitment to innovation[14] - Research and development expenses for the first three quarters of 2021 were ¥25,843,322.03, significantly higher than ¥6,973,726.69 in the same period of 2020, indicating a focus on innovation[37] Cash Flow and Assets - The company reported a cash flow from operating activities of RMB -198.10 million for the year-to-date period[6] - The total assets of the company reached RMB 4.13 billion, an increase of 5.66% from the end of the previous year[6] - As of September 30, 2021, the total current assets amounted to RMB 2,993,595,917.56, compared to RMB 2,928,180,427.26 at the end of 2020, reflecting an increase of approximately 2.24%[32] - The cash and cash equivalents decreased from RMB 661,752,739.80 at the end of 2020 to RMB 485,851,315.81, a decline of about 26.56%[32] - Accounts receivable stood at RMB 1,483,355,479.67, slightly down from RMB 1,514,619,042.21, indicating a decrease of approximately 2.05%[32] - Inventory increased from RMB 402,004,512.03 to RMB 547,401,779.13, representing a growth of around 36.2%[32] - The company reported a significant increase in other receivables, rising from RMB 191,731,932.03 to RMB 296,306,817.14, an increase of approximately 54.4%[32] - The company reported a decrease in cash and cash equivalents, with short-term borrowings at ¥584,806,356.94, down from ¥694,748,699.87 in the previous year[35] - The ending cash and cash equivalents balance for the third quarter of 2021 was CNY 481,432,715.81, a decrease from CNY 795,266,947.93 in the same period of 2020[43] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,631[24] - The largest shareholder, Saihai (Shanghai) Health Technology Co., Ltd., holds 37.18% of the shares, totaling 76,220,520 shares[24] Government Subsidies and Non-Operating Income - The company reported a government subsidy of 1.376 billion CNY for the current period, down from 6.296 billion CNY year-to-date[20] - Non-operating income and expenses for the current period amounted to -666,392.26 CNY, with a tax impact of 296,128.07 CNY[21] Corporate Governance - The company completed the election of the fourth board of directors and supervisory board, appointing new members including Mr. Wen Wei as the chairman[27] - The company has appointed Mr. Wang Zheng as the new general manager following the board restructuring[28] Stock Repurchase - The company plans to repurchase a total of 1,501,882 shares due to unmet performance targets in the 2019 restricted stock incentive plan[29] - The repurchase price for the first batch of restricted stocks is set at RMB 8.22 per share, plus interest from bank deposits[30] Financial Liabilities - Total liabilities rose to ¥2,324,847,563.06 in Q3 2021, up from ¥2,103,795,321.52 in Q3 2020, marking an increase of 10.5%[35] - Current liabilities reached CNY 1,388,178,679.65, including short-term borrowings of CNY 694,748,699.87 and accounts payable of CNY 400,135,722.13[46] - Total liabilities were CNY 2,103,795,321.52, with non-current liabilities at CNY 715,616,641.87[46] - The company’s long-term borrowings stand at CNY 254,246,969.72, indicating reliance on debt financing for growth[46]

Financial Performance - The company reported a significant increase in revenue for the first half of 2021, with a year-on-year growth of 25%[1]. - The company reported a revenue of 1.2 billion RMB for the first half of 2021, reflecting a year-on-year growth of 15%[20]. - The company's operating revenue for the first half of 2021 was approximately ¥1.198 billion, representing a year-on-year increase of 55.23% compared to ¥771.65 million in the same period last year[21]. - The company achieved a revenue of approximately CNY 1.198 billion, representing a year-on-year increase of 55.23%[69]. - The total revenue for the first half of 2021 reached 11,016,060.36 million RMB, showing a significant increase compared to the previous period[189]. - The net profit attributable to shareholders was reported at 1,489,172.77 million RMB, reflecting a growth of 402.77% year-over-year[189]. - The total comprehensive income for the period includes a significant amount of 102,969,700, reflecting overall financial health[195]. User Growth and Market Expansion - User data showed an increase in active users by 15% compared to the previous year, reaching a total of 1.5 million active users[1]. - The user base for the company's medical technology services expanded to 500 hospitals, an increase of 20% compared to the previous year[20]. - Market expansion plans include entering two new regions, which are projected to increase market share by 5%[1]. - The company is expanding its market presence in the EU, with plans to obtain CE certification for five products by Q4 2021[20]. - The company is actively involved in expanding its service offerings in the healthcare sector through strategic partnerships and contracts[115]. Research and Development - The company is investing in R&D, with a budget increase of 30% for new technology development[1]. - The company has invested 200 million RMB in R&D for new technologies, focusing on molecular diagnostics and biochemical testing[20]. - Research and development investment increased by 419.89% to ¥18.11 million in the first half of 2021[26]. - R&D investment increased to CNY 18.11 million in the first half of 2021, a 419.89% year-over-year increase[123]. - The company has signed a cooperation framework agreement with the Wuhan Institute of Virology to establish a long-term partnership in scientific research and technology transfer[117]. Strategic Initiatives - The company is considering strategic acquisitions to enhance its product portfolio and market presence[1]. - The company is exploring strategic acquisitions to enhance its supply chain capabilities, targeting a 15% increase in operational efficiency[20]. - The company is focusing on the development of smart hospital construction and medical smart supply chain services, aligning with healthcare reform policies[62]. - The company is enhancing its product lines in areas such as chemiluminescence and autoimmune diseases to capture more market share in the IVD sector[46]. Financial Stability and Investments - The company's total assets at the end of the reporting period were approximately ¥3.961 billion, reflecting a 1.40% increase from the previous year[21]. - The company's cash and cash equivalents at the end of the period amounted to ¥367,456,085, representing 9.28% of total assets, a decrease of 44.47% compared to the previous year[72]. - The company reported a net cash outflow from financing activities of CNY 64.84 million, primarily due to loan repayments[70]. - The company has established a technology licensing agreement with Inflammatix for exclusive rights in Greater China, enhancing its product development capabilities[77]. Operational Efficiency - The company is implementing a new data analytics platform to improve operational management and customer service efficiency[20]. - The company's internal supply chain management platform has been successfully implemented in over 30 subsidiaries, improving overall operational efficiency[59]. - The SPD model allows for zero inventory and proactive delivery, significantly optimizing cost structures and enhancing management efficiency for medical institutions[53]. Shareholder and Management Changes - The company appointed new management personnel, including Wang Zheng as the general manager and Liu Yuan as the board secretary[90]. - The company has not made any progress or changes regarding the stock incentive plan approved in 2019[93]. - The company has elected new non-independent directors and independent directors during the third extraordinary general meeting[90]. Risk Management - The management highlighted the importance of risk management strategies in navigating potential market challenges[1]. - The company is facing risks from increased market competition and longer accounts receivable cycles, which may impact cash flow and operational efficiency[84]. Compliance and Governance - The financial report has been confirmed as accurate and complete by the board of directors[1]. - The company has not received any penalties or corrective measures related to violations by its directors, supervisors, senior management, or controlling shareholders[106]. - The company has committed to ensuring that the return measures are effectively implemented and linked to the performance of the company[103].